The Potential of Microfluidics Technology in Cell and Gene Therapy, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn why the field is moving from ex vivo to in vivo gene and cell therapies—and what this shift means for scalability and accessibility. Attendees will gain insights into how microfluidics platforms like Cyto-Mine® are central to enabling in vivo therapies from vector development to stable cell line screening. The featured speaker will discuss what the future holds for decentralized, patient-friendly and high-impact gene therapy delivery. The speaker will also discuss how next-generation multiplexed microfluidic technologies are redefining cell-based assays.
TORONTO, May 21, 2025 /PRNewswire-PRWeb/ -- The future of cell and gene therapy (CGT) is rapidly shifting—from complex, costly ex vivo procedures to streamlined, scalable in vivo solutions. This webinar will explore how microfluidics technology is catalyzing this transformation, and how the integration of platforms like Cyto-Mine® is building the next generation of in vivo-ready therapeutics.
In traditional ex vivo cell therapies, patient cells must be harvested, engineered, expanded and reinfused—a process that is labour-intensive, time-consuming and difficult to scale. In contrast, in vivo therapy directly delivers gene editing tools or reprogramming vectors into the patient bypassing the need for cell manipulation outside the body.
In this webinar, the expert speaker will focus on a first-in-human clinical trial for treating tumors with NF2 mutations. They will discuss how microfluidics has been leveraged to develop a stable producer cell line for manufacturing therapeutic-grade vectors. These vectors can be used in in vivo gene therapy and in vivo CAR-T applications. Using Cyto-Mine®'s high-throughput single-cell analysis and isolation capabilities, scalable manufacturing platforms can be built. These platforms ensure the precision and consistency required for in vivo therapeutics.
This webinar will outline how microfluidics is not only optimizing vector production but also reshaping the entire therapeutic model—paving the way for faster, safer and more accessible treatments.
Register for this webinar today to discover how microfluidics is revolutionizing cell and gene therapy shifting from complex, costly procedures to more streamlined, in vivo solutions.
Join Dr. Luke Zhou, CEO, Santo Therapeutics, for the live webinar on Thursday, May 29, 2025, at 8am EDT (2pm CEST/EU-Central).
For more information, or to register for this event, visit The Potential of Microfluidics Technology in Cell and Gene Therapy.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks
Share this article